GWLL · GOLDENWELL BIOTECH INC COM
Goldenwell Biotech Inc (GWLL)
What's happening
- GWLL is down 9.09% today, trading at $0.70. — Live quote
- Reports earnings on 2026-09-10, 7 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-05-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -21.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -15.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on GWLL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $55 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $12 | $25.0K | $0 | $0 | $0 | $0 |
| Operating income | -$34.8K | -$31.3K | -$22.9K | -$5.9K | -$28.2K | -$36.4K | -$25.4K | -$21.0K |
| Net income | -$36.9K | -$17.6K | -$199.7K | -$8.0K | -$30.3K | -$38.5K | -$27.5K | $23.1K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | — | — | $0.00 | $0.00 | — |
| Operating margin | — | — | -$41.6K | — | — | — | — | — |
| Net margin | — | — | -$363.2K | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $29.0K | $18.8K | $36.1K | $220.4K | $251.3K | $191.9K | $224.2K | $179.4K |
| Total liabilities | $427.2K | $380.1K | $379.8K | $315.2K | $338.1K | $273.5K | $271.4K | $198.7K |
| Stockholders' equity | -$398.2K | -$361.3K | -$343.7K | -$144.0K | -$116.1K | -$85.8K | -$47.2K | -$20.9K |
| Total current assets | — | — | — | — | — | — | — | — |
| Total current liabilities | $100.0K | $100.0K | $101.9K | $39.4K | $64.4K | — | $1.9K | — |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | $0 | $0 | $174.7K | $174.8K | $174.8K | $174.8K | $174.8K | $174.7K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Accrued liabilities | $0 | $0 | — | — | — | — | — | — |
| Deferred revenue (current) | $0 | $100.0K | $1.9K | $37.5K | $62.5K | — | $0 | — |
| Long-term debt | — | — | — | — | — | $176.1K | $174.0K | — |
| Other non-current liabilities | $189.2K | $189.2K | $189.2K | $189.2K | $189.2K | $189.2K | $189.2K | — |
| Common stock & paid-in capital | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K |
| Retained earnings | -$1.7M | -$1.7M | -$1.7M | -$1.4M | -$1.4M | -$1.4M | -$1.4M | -$1.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.3K | -$13.4K | -$18.8K | -$30.9K | $59.4K | -$32.3K | -$25.4K | -$68.7K |
| Financing cash flow | $45.0K | $0 | $0 | $0 | $0 | $0 | $70.0K | $47.1K |
| Change in accounts receivable | $0 | $0 | — | $0 | $0 | $0 | — | $0 |
| Change in inventory | $0 | -$174.7K | -$43 | $0 | $0 | $0 | $73 | -$227 |
| Change in accounts payable | $0 | $0 | — | $0 | $0 | $0 | — | $0 |
| Debt issued | $0 | $0 | — | $0 | $0 | $0 | $70.0K | $49.2K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $55 | $139 | $1.8K | $47.8K | $16.0K |
| Gross profit | $12 | $64 | $666 | $25.2K | $8.4K |
| Operating income | -$113.3K | -$123.1K | -$115.8K | -$985.1K | -$118.3K |
| Net income | -$296.5K | -$131.5K | -$117.4K | -$985.1K | -$117.0K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | — | — |
| Operating margin | -$206.0K | -$88.6K | -$6.3K | -$2.1K | -$741 |
| Net margin | -$539.0K | -$94.6K | -$6.4K | -$2.1K | -$733 |
Balance sheet
| Line item | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|
| Total assets | $36.1K | — | — | — | $224.2K |
| Total liabilities | $379.8K | — | — | — | $271.4K |
| Stockholders' equity | -$343.7K | -$144.0K | -$116.1K | -$85.8K | -$47.2K |
| Total current liabilities | $101.9K | — | — | — | $1.9K |
| Cash & equivalents | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Inventory | $174.7K | — | — | — | $174.8K |
| Intangible assets | — | — | — | — | — |
| Accounts payable | $0 | — | — | — | $0 |
| Deferred revenue (current) | $100.0K | — | — | — | — |
| Long-term debt | — | — | — | — | $174.0K |
| Other non-current liabilities | $189.2K | — | — | — | $189.2K |
| Common stock & paid-in capital | $9.9K | — | — | — | $9.9K |
| Retained earnings | -$1.7M | — | — | — | -$1.4M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.6K | -$123.1K | -$113.2K | -$1.1M | -$205.1K |
| Financing cash flow | $0 | $119.2K | $120.4K | $905.0K | $170.1K |
| Change in accounts receivable | — | — | $0 | $0 | $0 |
| Change in inventory | -$43 | -$75 | -$1.2K | $22.6K | $198.7K |
| Change in accounts payable | — | — | — | -$111.5K | $111.5K |
| Debt issued | — | $119.2K | $70.0K | $20.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding GWLL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 12:00 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-07-01 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-19 | View on SEC.gov → |
| 2025-12-08 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-09-12 | 10-Q | 2025-06-30 | View on SEC.gov → |
| 2025-08-19 | 8-K | 2025-07-24 | View on SEC.gov → |
| 2025-05-27 | 10-Q | 2025-03-31 | View on SEC.gov → |
| 2025-05-15 | 10-K | 2024-12-31 | View on SEC.gov → |
| 2025-01-23 | 8-K | 2025-01-23 | View on SEC.gov → |
| 2024-11-26 | 10-Q | 2024-09-30 | View on SEC.gov → |
| 2024-11-15 | 8-K | 2024-11-13 | View on SEC.gov → |
Recent news
Headlines about GWLL (GOLDENWELL BIOTECH INC COM). Links open the publisher — we don’t host full articles.